Anixa is a biotechnology company developing a number of programs addressing cancer and infectious disease.
Anixa's therapeutics portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therape...
Anixa is a biotechnology company developing a number of programs addressing cancer and infectious disease.
Anixa's therapeutics portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.